Klibanski Appointed Interim President, CEO of Partners HealthCare


Anne Klibanski

Anne Klibanski, MD, will serve as the interim president and CEO of Partners HealthCare while the organization works to identify the permanent president and CEO.

Klibanski has been a systemwide leader of research, teaching and clinical missions, as well as a distinguished clinician and teacher. In her current role as chief academic officer for Partners, a position she has held since 2012, Klibanski is a leader who understands the need for clinical integration and collaboration. She oversees a research enterprise of more than $1.8 billion annually, sets strategy and is responsible for Partners HealthCare Innovation. Klibanski is also the chief of Neuroendocrine at MGH and is recognized internationally for her high-impact research in neuroendocrine disorders and pituitary tumors. She serves as the Laurie Carrol Guthart Professor of Medicine and an academic dean for Partners at Harvard Medical School. Last month, Klibanski was named to Modern HealthCare’s Top 25 Women Leaders.

Klibanski will now helm the largest private employer in Massachusetts. With 74,000 employees dedicated to providing unparalleled health care, Partners is also the global leader in life science research and medical training. As the interim CEO and leader of this large and diverse organization, Klibanski will work closely with hospital presidents, clinicians, researchers and administrative leadership, while also guiding important initiatives such as Partners 2.0. Klibanski is a demonstrated leader in these efforts and is overseeing large clinical and executive teams crafting a system-wide approach to future state radiology, pathology and anesthesiology structure and investments. Working with renowned experts in digital health across our system, she is committed to driving value to our patients, faculty and staff across Partners in this critical area. Klibanski is anticipated to be in this role for approximately one year while Partners completes the search for its permanent CEO.


John F. Keaney, Jr.

Keaney Appointed New Chief of Cardiovascular Medicine

John F. Keaney, Jr., MD, has been named chief of the Division of Cardiovascular Medicine in the Department of Medicine and executive director of the Heart and Vascular Center (HVC) at the Brigham. Keaney will assume his new role on August 1, 2019.

Keaney will be returning to the Brigham. A graduate of the Yale University School of Medicine, Keaney completed both his residency in internal medicine and his fellowship in cardiology at the Brigham. Following his training, Keaney joined the faculty at Brockton/West Roxbury VA Medical Center in 1992, before moving to Boston University Medical Center Hospital (BMC) in 1994. During different periods at BMC, Keaney served as co-director of the Cardiology Fellowship Program, associate chief of the Cardiology Section, and vice chair for Research Affairs for the Department of Medicine. In 2007, Keaney was recruited to be chief of the Division of Cardiovascular Medicine at University of Massachusetts Medical School and UMass Memorial Healthcare. Since 2014, he has also served as director of the Heart and Vascular Center of Excellence at UMass Memorial Healthcare and as the Mary C. DeFeudis Professor of Biomedical Research at the University of Massachusetts Medical School.

An active physician-scientist, Keaney is a strong proponent of the tri-partite mission. He is an active and funded investigator who has completed groundbreaking work in vascular and redox biology. Keaney has also been the recipient of a range major awards locally and nationally, and currently serves as an associate editor for the New England Journal of Medicine.

Keaney will be succeeding Calum MacRae, MD, PhD, who served as chief of the Division of Cardiovascular Medicine from 2014 to 2018, and Samuel Goldhaber, MD, who has served as interim chief from 2018 to 2019.